Drug class

Phosphate Binder Agents

Phosphate binder agents are a therapeutic class of medications used to control serum phosphorus levels in patients with hyperphosphatemia. Read more about Phosphate Binder Agents

70 drugs in this class 46 manufacturers

Advertisement

Drugs in Phosphate Binder Agents

Showing 37–45 of 70 drugs

SEVELAMER CARBONATE

PHOSPHATE BINDER AGENTS · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
AVPAK

SEVELAMER CARBONATE

PHOSPHATE BINDER AGENTS · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
AHP

SEVELAMER HCL

PHOSPHATE BINDER AGENTS · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
AHP

SEVELAMER CARBONATE

PHOSPHATE BINDER AGENTS · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
STRIDES PHARMA

CALCIUM ACETATE

CALCIUM · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
RISING PHARM

SEVELAMER HCL

PHOSPHATE BINDER AGENTS · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
AUROBINDO PHARM

SEVELAMER CARBONATE

PHOSPHATE BINDER AGENTS · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
PRECISION DOSE

SEVELAMER HCL

PHOSPHATE BINDER AGENTS · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
LUPIN PHARMACEU

LANTHANUM CARBONATE

PHOSPHATE BINDER AGENTS · RENAL OSTEODYSTROPHY WITH HYPERPHOSPHATEMIA
CIPLA USA, INC.
Filter & compare in the drug finder → Opens the drug finder with Phosphate Binder Agents preselected. Add indication or manufacturer filters there.

About Phosphate Binder Agents.

Phosphate binder agents are a therapeutic class of medications used to control serum phosphorus levels in patients with hyperphosphatemia.

These agents work primarily within the gastrointestinal tract by binding dietary phosphate to form insoluble complexes, which prevents systemic absorption and promotes elimination through the feces.

The class encompasses calcium-based binders, non-calcium polymers such as sevelamer, lanthanum carbonate, and iron-based formulations.

They are principally indicated for the management of hyperphosphatemia in individuals with advanced chronic kidney disease, particularly those undergoing hemodialysis or peritoneal dialysis, to prevent complications such as secondary hyperparathyroidism, vascular calcification, and renal osteodystrophy.